Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies

Bibliography

• Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis 2007;45:S89-95
   PubMed Web of Science ®Google Scholar
• Petzinger E, Geyer J. Drug transporters in pharmacokinetics. Naunyn Schmiedebergs Arch Pharmacol 2006;372:465-75
   PubMed Web of Science ®Google Scholar
• Hu L, Zhuo W, He YJ, et al. Pharmacogenetics of P450 oxidoreductase: implications in drug metabolism and therapy. Pharmacogenet Genomics 2012;22:812-19
   PubMed Web of Science ®Google Scholar
• Chen HS, Gross JF. Physiologically based pharmacokinetic models for anticancer drugs. Cancer Chemother Pharmacol 1979;2:85-94
   PubMed Web of Science ®Google Scholar
• Jones HM, Mayawala K, Poulin P. Dose selection based on physiologically based pharmacokinetic (PBPK) approaches. AAPS J 2013;15:377-87
   PubMed Web of Science ®Google Scholar
• Yeo KR, Jamei M, Rostami-Hodjegan A. Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Rev Clin Pharmacol 2013;6:143-57
   PubMed Web of Science ®Google Scholar
• Paine SW, Barton P, Bird J, et al. A rapid computational filter for predicting the rate of human renal clearance. J Mol Graph Model 2010;29:529-37
   PubMed Web of Science ®Google Scholar
• Price PS, Conolly RB, Chaisson CF, et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 2003;33:469-503
   PubMed Web of Science ®Google Scholar
• Bosgra S, van Eijkeren J, Bos P, et al. An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry. Crit Rev Toxicol 2012;42:751-67
   PubMed Web of Science ®Google Scholar
• Willmann S, Hohn K, Edginton A, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 2007;34:401-31
   PubMed Web of Science ®Google Scholar
• Sánchez-Recio MM, Colino C-I, Sánchez-Navarro A. A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin. J Antimicrob Chemother 2000;4:321-8
   Google Scholar
• Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011;55:4782-898
   PubMed Web of Science ®Google Scholar
• Perry T, Schentag J. Clinical use of ceftriaxone. Clin Pharmacokinet 2001;40:685-94
   PubMed Web of Science ®Google Scholar
• Vella-Brincat JWA, Begg EJ, Kirkpatrick CMJ, et al. Protein binding of cefazolin is saturable in vivo both between and within patients. Br J Clin Pharmacol 2007;63:753-7
   PubMed Web of Science ®Google Scholar
• Dudley MN, Shyu WC, Nightingale CH, Quintiliani R. Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans. Antimicrob Agents Chemother 1986;30:565-9
   PubMed Web of Science ®Google Scholar
• Burkhardt O, Brunner M, Schmidt S, et al. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J Antimicrob Chemother 2006;58:632-6
   PubMed Web of Science ®Google Scholar
• Mukker JK, Singh RP, Derendorf H. Determination of atypical nonlinear plasma–protein-binding behavior of tigecycline using an in vitro microdialysis technique. J Pharm Sci 2014;103:1013-19
   PubMed Web of Science ®Google Scholar
• Marshall JD, Kearns GL. Developmental pharmacodynamics of cyclosporine. Clin Pharmacol Ther 1999;66:66-75
   PubMed Web of Science ®Google Scholar
• Johnson TN. Modelling approaches to dose estimation in children. Br J Clin Pharmacol 2005;59(6):663-9
   PubMed Web of Science ®Google Scholar
• Andrew MA, Easterling TR, Carr DB, et al. Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin Pharmacol Ther 2007;81:547-56
   PubMed Web of Science ®Google Scholar
• Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009;41:67-76
   PubMed Web of Science ®Google Scholar
• Faulkner CM, Cox HL, Williamson JC. Unique aspects of antimicrobial use in older adults. Clin Infect Dis 2005;40:997-1004
   PubMed Web of Science ®Google Scholar
• Thompson CM, Johns DO, Sonawane B, et al. Database for physiologically based pharmacokinetic (PBPK) modeling: physiological data for healthy and health-impaired elderly. J Toxicol Environ Health B Crit Rev 2009;12:1-24
   PubMed Web of Science ®Google Scholar
• Bolger MB, Irwin R, Schneider LS, Brinton RD. GastroPlus PBPK/PD Model applied to estimating dose for an elderly population in an Alzheimer’s disease clinical trial. Population Approach Group of Europe (PAGE) 2012; Venice, Italy; 2012
   Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157-67
   PubMed Web of Science ®Google Scholar
• Salem F, Johnson TN, Barter ZE, et al. Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions. J Clin Pharmacol 2013;53:857-65
   PubMed Web of Science ®Google Scholar
• Siccardi M, Almond L, Khoo S, et al. Pharmacokinetics of efavirenz dose optimization in pediatric patients using an in-vitro in vivo extrapolation model. 19th February 2012 Conference on Retroviruses and Opportunistic Infections 2012; Seattle, WA, USA
   Google Scholar
• Huttunen R, Karppelin M, Syrjanen J. Obesity and nosocomial infections. J Hosp Infect 2013;85:8-16
   PubMed Web of Science ®Google Scholar
• Young JF, Luecke RH, Pearce BA, et al. Human organ/tissue growth algorithms that include obese individuals and black/white population organ weight similarities from autopsy data. J Toxicol Environ Health A 2009;72:527-40
   PubMed Web of Science ®Google Scholar
• de Roche M, Siccardi M, Stoeckle M, et al. Efavirenz in an obese HIV-infected patient--a report and an in vitro-in vivo extrapolation model indicate risk of underdosing. Antivir Ther 2012;17:1381-4
   PubMed Web of Science ®Google Scholar
• Luecke RH, Wosilait WD, Pearce BA, Young JF. A physiologically based pharmacokinetic computer model for human pregnancy. Teratology 1994;49:90-103
   PubMedGoogle Scholar
• Andrew MA, Hebert MF, Vicini P. Physiologically based pharmacokinetic model of midazolam disposition during pregnancy. Conf Proc IEEE Eng Med Biol Soc 2008;2008:5454-7
   PubMedGoogle Scholar
• Ke AB, Nallani SC, Zhao P, et al. Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. Br J Clin Pharmacol 2014;77:554-70
   PubMed Web of Science ®Google Scholar
• Hanada K, Nakai K, Tanaka H, et al. Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development. Drug Metab Pharmacokinet 2012;27:301-6
   PubMed Web of Science ®Google Scholar
• Nagasue N, Dhar DK, Makino Y, et al. Overexpression of P-glycoprotein in adenomatous hyperplasia of human liver with cirrhosis. J Hepatol 1995;22:197-201
   PubMed Web of Science ®Google Scholar
• Grude P, Conti F, Mennecier D, et al. MDR1 gene expression in hepatocellular carcinoma and the peritumoral liver of patients with and without cirrhosis. Cancer Lett 2002;186:107-13
   PubMed Web of Science ®Google Scholar
• Kojima H, Nies AT, Konig J, et al. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J Hepatol 2003;39:693-702
   PubMed Web of Science ®Google Scholar
• Zollner G, Fickert P, Silbert D, et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 2003;38:717-27
   PubMed Web of Science ®Google Scholar
• Ogasawara K, Terada T, Katsura T, et al. Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. Drug Metab Pharmacokinet 2010;25:190-9
   PubMed Web of Science ®Google Scholar
• Kurzawski M, Dziedziejko V, Post M, et al. Expression of genes involved in xenobiotic metabolism and transport in end-stage liver disease: up-regulation of ABCC4 and CYP1B1. Pharmacol Rep 2012;64:927-39
   PubMed Web of Science ®Google Scholar
• Walsh KM, Leen E, MacSween RN, Morris AJ. Hepatic blood flow changes in chronic hepatitis C measured by duplex Doppler color sonography: relationship to histological features. Dig Dis Sci 1998;43:2584-90
   PubMed Web of Science ®Google Scholar
• Xu C, Quinney SK, Guo Y, et al. CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling. Drug Metab Dispos 2013;41:2004-11
   PubMed Web of Science ®Google Scholar
• Siccardi M, Almond L, Schipani A, et al. Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model. Clin Pharmacol Ther 2012;92:494-502
   PubMed Web of Science ®Google Scholar
• Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-11
   PubMed Web of Science ®Google Scholar
• Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009;68:906-15
   PubMed Web of Science ®Google Scholar
• Li-Wan-Po A, Girard T, Farndon P, et al. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol 2010;69:222-30
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Krauss RM, Roden DM, et al. When good drugs go bad. Nature 2007;446:975-7
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Draft guidance for industry: drug interaction studies - drug design, data analysis, and implications for dosing and labeling. U.S. Food and Drug Administration, Silver Spring, MD; 2012
   Google Scholar
• European Medicines Agency. Guideline on the investigation of drug interactions. European Medicines Agency, Canary Wharf, London, UK; 2012
   Google Scholar
• Huang SM, Rowland M. The role of physiologically based pharmacokinetic modeling in regulatory review. Clin Pharmacol Ther 2012;91:542-9
   PubMed Web of Science ®Google Scholar
• Jamei M, Marciniak S, Feng K, et al. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 2009;5:211-23
   PubMed Web of Science ®Google Scholar
• Guo H, Liu C, Li J, et al. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions. J Pharm Sci 2013;102:2819-36
   PubMed Web of Science ®Google Scholar
• Perdaems N, Blasco H, Vinson C, et al. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin Pharmacokinet 2010;49:239-58
   PubMed Web of Science ®Google Scholar
• Quinney SK, Zhang X, Lucksiri A, et al. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos 2010;38:241-8
   PubMed Web of Science ®Google Scholar
• Vieira ML, Zhao P, Berglund EG, et al. Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor. Clin Pharmacol Ther 2012;91:700-8
   PubMed Web of Science ®Google Scholar
• Siccardi M, Marzolini C, Seden K, et al. Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. Clin Pharmacokinet 2013;52:583-92
   PubMed Web of Science ®Google Scholar
• Zhao P, Ragueneau-Majlessi I, Zhang L, et al. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol 2009;49:351-9
   PubMed Web of Science ®Google Scholar
• Siccardi M, Rajoli RKR, Curley P, et al. Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. Future Virol 2013;8:871-90
   Web of Science ®Google Scholar
• Vossen M, Sevestre M, Niederalt C, et al. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Theor Biol Med Model 2007;4:13
   PubMed Web of Science ®Google Scholar
• Yamashita F, Sasa Y, Yoshida S, et al. Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data. PLoS One 2013;8:e70330
   PubMed Web of Science ®Google Scholar
• Yang Z, Vakkalagadda B, Shen G, et al. Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations. J Clin Pharmacol 2013;53:217-27
   PubMed Web of Science ®Google Scholar
• Baneyx G, Parrott N, Meille C, et al. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration. Eur J Pharm Sci 2014;56:1-15
   PubMed Web of Science ®Google Scholar
• Han B, Mao J, Chien JY, Hall SD. Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. Drug Metab Dispos 2013;41:1329-38
   PubMed Web of Science ®Google Scholar
• Shardlow CE, Generaux GT, Patel AH, et al. Impact of physiologically based pharmacokinetic modeling and simulation in drug development. Drug Metab Dispos 2013;41:1994-2003
   PubMed Web of Science ®Google Scholar
• Varma MV, Lin J, Bi YA, et al. Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin. Drug Metab Dispos 2013;41:966-74
   PubMed Web of Science ®Google Scholar
• Siccardi M, Olagunju A, Seden K, et al. Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. In Silico Pharmacol 2013;1:4
   Google Scholar
• Rekic D, Roshammar D, Mukonzo J, Ashton M. In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. Br J Clin Pharmacol 2011;71:536-43
   PubMed Web of Science ®Google Scholar
• Damle B, Varma MV, Wood N. Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use. Antimicrob Agents Chemother 2011;55:5172-7
   PubMed Web of Science ®Google Scholar
• Morgan ET, Goralski KB, Piquette-Miller M, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 2008;36:205-16
   PubMed Web of Science ®Google Scholar
• Chu X, Bleasby K, Evers R. Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opin Drug Metab Toxicol 2013;9:237-52
   PubMed Web of Science ®Google Scholar
• Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 2002;42:620-43
   PubMed Web of Science ®Google Scholar
• McConnell EL, Fadda HM, Basit AW. Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm 2008;364:213-26
   PubMed Web of Science ®Google Scholar
• Gazzaniga A, Iamartino P, Maffione G, Sangalli ME. An oral delayed-action formulation for release in the colon. Boll Chim Farm 1993;132:78-80
   PubMedGoogle Scholar
• Philip AK, Philip B. Colon targeted drug delivery systems: a review on primary and novel approaches. Oman Med J 2010;25:79-87
   PubMedGoogle Scholar
• Gao P, Nie X, Zou M, et al. Recent advances in materials for extended-release antibiotic delivery system. J Antibiot (Tokyo) 2011;64:625-34
   PubMed Web of Science ®Google Scholar
• Peng HT, Bouak F, Vartanian O, Cheung B. A physiologically based pharmacokinetics model for melatonin--effects of light and routes of administration. Int J Pharm 2013;458:156-68
   PubMed Web of Science ®Google Scholar
• Lin Z, Li M, Gehring R, Riviere JE. Development and application of a multiroute physiologically based pharmacokinetic model for oxytetracycline in dogs and humans. J Pharm Sci 2015;104:233-43
   PubMed Web of Science ®Google Scholar
• Darwich AS, Neuhoff S, Jamei M, Rostami-Hodjegan A. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” model. Curr Drug Metab 2010;11:716-29
   PubMed Web of Science ®Google Scholar
• Moss DM, Siccardi M, Back DJ, Owen A. Predicting intestinal absorption of raltegravir using a population-based ADME simulation. J Antimicrob Chemother 2013;68:1627-34
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis 2009;48:489-92
   PubMed Web of Science ®Google Scholar
• Moss DM, Siccardi M, Murphy M, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother 2012;56:3020-6
   PubMed Web of Science ®Google Scholar
• Kiser JJ, Bumpass JB, Meditz AL, et al. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother 2010;54:4999-5003
   PubMed Web of Science ®Google Scholar
• Held J, Kreidenweiss A, Mordmuller B. Novel approaches in antimalarial drug discovery. Expert Opin Drug Discov 2013;8:1325-37
   PubMed Web of Science ®Google Scholar
• Barrios-Payan J, Saqui-Salces M, Jeyanathan M, et al. Extrapulmonary locations of mycobacterium tuberculosis DNA during latent infection. J Infect Dis 2012;206:1194-205
   PubMed Web of Science ®Google Scholar
• Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther 2011;16:1149-67
   PubMed Web of Science ®Google Scholar
• Kethireddy S, Andes D. CNS pharmacokinetics of antifungal agents. Expert Opin Drug Metab Toxicol 2007;3:573-81
   PubMed Web of Science ®Google Scholar
• Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 2004;16:1-13
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U. Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses? Curr Opin Pharmacol 2007;7:498-504
   PubMed Web of Science ®Google Scholar
• Musther H, Olivares-Morales A, Hatley OJ, et al. Animal versus human oral drug bioavailability: do they correlate? Eur J Pharm Sci 2013;57:280-91
   PubMed Web of Science ®Google Scholar
• Mouton JW, Theuretzbacher U, Craig WA, et al. Tissue concentrations: do we ever learn? J Antimicrob Chemother 2008;61:235-7
   PubMed Web of Science ®Google Scholar
• Peyret T, Poulin P, Krishnan K. A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals. Toxicol Appl Pharmacol 2010;249:197-207
   PubMed Web of Science ®Google Scholar
• Jones H, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst Pharmacol 2013;2:e63
   PubMedGoogle Scholar
• Westerhout J, Ploeger B, Smeets J, et al. Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. AAPS J 2012;14:543-53
   PubMed Web of Science ®Google Scholar
• Levitt DG. The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol 2003;3:3
   PubMedGoogle Scholar
• Tsuji A, Yoshikawa T, Nishide K, et al. Physiologically based pharmacokinetic model for beta-lactam antibiotics I: Tissue distribution and elimination in rats. J Pharm Sci 1983;72:1239-52
   PubMed Web of Science ®Google Scholar
• Edginton AN, Ahr G, Willmann S, Stass H. Defining the role of macrophages in local moxifloxacin tissue concentrations using biopsy data and whole-body physiologically based pharmacokinetic modelling. Clin Pharmacokinet 2009;48:181-7
   PubMed Web of Science ®Google Scholar
• Velkov T, Bergen PJ, Lora-Tamayo J, et al. PK/PD models in antibacterial development. Curr Opin Microbiol 2013;16:573-9
   PubMed Web of Science ®Google Scholar
• Coenye T, Nelis HJ. In vitro and in vivo model systems to study microbial biofilm formation. J Microbiol Methods 2010;83:89-105
   PubMed Web of Science ®Google Scholar
• Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002;19:261-8
   PubMed Web of Science ®Google Scholar
• Trivedi A, Lee RE, Meibohm B. Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives. Expert Rev Clin Pharmacol 2013;6:159-70
   PubMed Web of Science ®Google Scholar
• Chetty M, Rose RH, Abduljalil K, et al. Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability. Front Pharmacol 2014;5:258
   PubMed Web of Science ®Google Scholar
• Smith PF, Ogundele A, Forrest A, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3’,3’-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother 2007;51:3574-81
   PubMed Web of Science ®Google Scholar
• Nielsen EI, Viberg A, Lowdin E, et al. Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob Agents Chemother 2007;51:128-36
   PubMed Web of Science ®Google Scholar
• Nielsen EI, Cars O, Friberg LE. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother 2011;55:4619-30
   PubMed Web of Science ®Google Scholar
• Nielsen EI, Cars O, Friberg LE. Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model. Antimicrob Agents Chemother 2011;55:1571-9
   PubMed Web of Science ®Google Scholar
• Wongsrichanalai C, Varma JK, Juliano JJ, et al. Extensive drug resistance in malaria and tuberculosis. Emerg Infect Dis 2010;16:1063-7
   PubMedGoogle Scholar
• Huang SM, Abernethy DR, Wang Y, et al. The utility of modeling and simulation in drug development and regulatory review. J Pharm Sci 2013;102:2912-23
   PubMed Web of Science ®Google Scholar
• Shelton MJ, Akbari B, Hewitt RG, et al. Eradication of Helicobacter pylori is associated with increased exposure to delavirdine in hypochlorhydric HIV-positive patients. J Acquir Immune Defic Syndr 2000;24:79-82
   PubMed Web of Science ®Google Scholar
• Gandhi A, Moorthy B, Ghose R. Drug disposition in pathophysiological conditions. Curr Drug Metab 2012;13:1327-44
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004;57:6-14
   PubMed Web of Science ®Google Scholar
• Schoen JC, Erlandson KM, Anderson PL. Clinical pharmacokinetics of antiretroviral drugs in older persons. Expert Opin Drug Metab Toxicol 2013;9:573-88
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010;49:71-87
   PubMed Web of Science ®Google Scholar
• Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000;39:215-31
   PubMed Web of Science ®Google Scholar
• Abduljalil K, Furness P, Johnson TN, et al. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet 2012;51:365-96
   PubMed Web of Science ®Google Scholar